$ 150 M
32
270 M
WHO
Egypt's Most Ambitious Vaccine Complex
Gennvax is building Egypt’s largest fully integrated vaccine manufacturing complex at Al-Ain Al-Sokhna Industrial Area strategically located 12km from Al-Sokhna port and within reach of the entire African and Middle Eastern market.
Our mission is simple: end the region’s dependency on imported vaccines by producing world-class immunisations at home on African soil, to global standards.
- 49,042 m² state-of-the-art manufacturing campus
- 32 vaccines across critical disease categories
- Technology transfer partnerships with 15+ global providers
- Full compliance with WHO, EMA and FDA GMP standards
Where Vision Becomes Infrastructure
Rising from the desert at Al-Ain Al-Sokhna, the Gennvax complex is a landmark of African industrial ambition — 49,042 m² of world-class vaccine manufacturing, 12km from the Red Sea.
Our mission is simple: end the region’s dependency on imported vaccines by producing world-class immunisations at home — on African soil, to global standards.
- 49,042 m² state-of-the-art manufacturing campus
- 32 vaccines across critical disease categories
- Technology transfer partnerships with 15+ global providers
- Full compliance with WHO, EMA and FDA GMP standards
49,042 m²
10,727 m²
18,701 m²
Oct '27
A Campus Built for Scale
Located in the first industrial area of Orascom’s Al-Sokhna zone, the Gennvax campus is designed for phased expansion with 60% of the plot available for future growth as production scales to meet regional demand.
Construction commenced February 2026, with project completion targeted for October 2027. All required licenses from the Suez Canal Economic Zone authority are in place.
Covering all local and regional National Immunisation Programme requirements plus non-obligatory vaccines — sourced through 15 technology transfer providers worldwide.
Single Dose
Single Dose
10 Dose Vial
10 Dose · Pentavalent
Single Dose
5 Dose Vial
Single Dose · Seasonal
Single Dose · Seasonal
Single Dose
10 Dose Vial
WHO
World Health Organization
GMP Prequalification
EMA
European Medicines Agency
GMP Compliance
FDA
US Food & Drug Administration
Current GMP
Our Quality Management System (QMS)
The QMS is designed from the ground up to meet WHO, EMA and FDA expectations — ensuring consistent product quality across every process, from raw material sourcing to final batch release.
Built to Meet the World's Highest Standards
Every aspect of the Gennvax facility — from design concept through to production — has been developed with quality compliance as the primary driver, not an afterthought.
State-of-the-Art Facility Design
Clear, validated flows of materials, products and people — designed to prevent contamination at every step. Concept, basic and detailed design phases all completed with compliance reports.
Automation & Process Control
Latest equipment with full automation control and utilities engineered to the highest purity specifications — purified water, clean steam, controlled environments.
Validation & Documentation
Comprehensive Validation Master Plan (VMP) and Contamination Control Strategy (CCS) written and approved at concept stage — ahead of construction.
Expert Quality Team
7 international specialists in aseptic manufacturing, vaccine control, GMP/GDP, regulatory affairs and post-marketing surveillance — with proven track records.
As part of its commitment to strengthening regulatory partnerships across Africa, Gennvax held a high-level meeting with the Medicines Control Authority of Zimbabwe (MCAZ), represented by Dr. Zivanai Makoni, Head of the Evaluation and Registration Division.
Gennvax management and team held a high-level meeting with the Ministry of Health of Uganda, including Hon. Margaret Muhanga Mugisa, Minister of State for Primary Health Care, and Hon. Anifa Kawooya Bangirana, Minister of State for Health in charge of General Duties.
Gennvax is advancing its strategic partnership with Kenya’s Ministry of Health, with the completion of a Memorandum of Understanding (MOU) currently in process. This collaboration focuses on enhancing vaccine access, supporting national health priorities, and moving toward self-sufficiency in vaccine production.